Does an intra‑articular corticosteroid (cortisone) injection provide symptomatic relief for grade 3 chondromalacia of the medial and lateral femoral condyles?

Intra-articular Corticosteroid Injection for Grade 3 Chondromalacia

Cortisone injections can provide short-term symptomatic relief (2-4 weeks on average) for grade 3 chondromalacia of the femoral condyles, but the evidence suggests this benefit is modest, not sustained beyond 3 months, and may be associated with accelerated cartilage loss with repeated use.

Evidence-Based Recommendation

The 2020 ACR/Arthritis Foundation guidelines do not specifically address corticosteroid injections for chondromalacia, focusing instead on osteoarthritis 1. However, the 2021 EULAR recommendations acknowledge that intra-articular glucocorticoids (IA GC) are used for various joint disorders, with important caveats about repeated use 2.

Short-Term Efficacy (≤3 months)

• Corticosteroid injections do provide initial pain relief, but this effect is:
  • Modest compared to saline placebo 3
  • Limited to 2-4 weeks duration on average 3
  • Not meaningfully different from placebo at 12-24 months 4

Long-Term Concerns (>3 months)

The most concerning finding is the potential for harm with repeated injections:

• Recent evidence shows intra-articular corticosteroids are associated with greater MRI-assessed cartilage thickness loss compared to saline injections 3
• Recurrent corticosteroid injections demonstrate inferior or non-superior symptom relief compared to other injectables (including placebo) at 3 months and beyond 4
• Long-term use should be avoided to prevent chondrotoxicity and further progression of cartilage damage 5

Clinical Decision Algorithm

If considering a cortisone injection for grade 3 chondromalacia:

1. Use only as a time-limited intervention when other conservative measures have failed
2. Limit to 3-4 injections per year maximum (general accepted rule, though not evidence-based) 2
3. Avoid repeated injections - the evidence shows diminishing returns and potential harm 4
4. Counsel patients that:
   • Pain relief will likely last only 2-4 weeks
   • Repeated injections may accelerate cartilage loss
   • This is a bridge therapy, not a disease-modifying treatment

Important Caveats

Safety Considerations from FDA Labeling:

• Musculoskeletal effects: Corticosteroids decrease bone formation and increase bone resorption, potentially leading to osteoporosis 6
• Use the lowest possible dose to control symptoms 6
• Diabetic patients: Monitor glucose levels days 1-3 post-injection due to transient hyperglycemia 2, 6

Post-Injection Care:

• Avoid overuse of the injected joint for 24 hours, but immobilization is discouraged 2
• Normal activity after 24-48 hours is appropriate

Alternative Considerations

The evidence for grade 3 chondromalacia specifically is limited 7. The systematic review on chondromalacia found that:

• Hyaluronic acid probably has little to no effect on pain or symptom severity 7
• PRP and prolotherapy lack placebo-controlled trials, precluding firm conclusions 7

Bottom Line

A single cortisone injection may provide 2-4 weeks of modest pain relief for grade 3 chondromalacia, but this should be viewed as a short-term bridge therapy only. Repeated injections are not supported by evidence and may accelerate cartilage damage 5, 4, 3. The decision to inject should weigh the brief symptomatic benefit against the risk of chondrotoxicity, particularly in younger patients with grade 3 disease who have substantial remaining cartilage to preserve.